Table 2 Results of diagnostic tests in critically ill patients with Aspergillus-positive culture in respiratory tract samples (PAC group) and only positive galactomannan without Aspergillus growth in the BALF (OPG group)
All patients | PAC group | OGP group | P value | |
|---|---|---|---|---|
Variable | (n = 85) | (n = 43) | (n = 42) | |
Galactomannan | ||||
Galactomannan test in BALF, positive, n (%) | 77 (90.6) | 35 (81.4) | 42 (100) | 0.049 |
Galactomannan test in BALF, titre EIA (IQR) | 3.4 (1.0–6.3) | 5.9 (3.2–7.0) | 1.7 (0.9–4.5) | <0.001 |
Galactomannan test in serum, positive, n (%) | 16 (18.8) | 11 (25.6) | 5 (11.9) | 0.096 |
Galactomannan test in serum, titre EIA (IQR) | 1.9 (1.0–3.8) | 2.3 (1.2–5.0) | 1.0 (0.7–3.1) | 0.181 |
Aspergillus-PCR in BALF | ||||
Performed, n | 47 | 24 | 23 | |
Positive, n (%) | 19 (40.4) | 15 (62.5) | 4 (17.3) | 0.002 |
Bronchoscopy | ||||
Aspergillus tracheobronchitis, n (%) | 8 (9.4) | 7 (16.3) | 1 (2.4) | 0.058 |
CT scan | ||||
Performed, n | 81 | 40 | 41 | |
Nodular infiltrate(s), n (%) | 23 (28.4) | 12 (30.0) | 11 (26.8) | 0.752 |
Halo sign, n (%) | 11 (13.6) | 4 (10.0) | 7 (17.1) | 0.519 |
Wedge-shaped pleura associated consolidations, n (%) | 16 (19.8) | 7 (17.5) | 9 (22.0) | 0.615 |
Focal ground-glass opacities (%) | 26 (32.1) | 13 (32.5) | 13 (31.7) | 0.939 |
Caverns/air-crescent sign, n (%) | 8 (9.9) | 6 (15.0) | 2 (4.9) | 0.155 |
Tree-in-bud pattern/centrilobular nodules, n (%) | 14 (17.3) | 5 (12.5) | 9 (22.0) | 0.379 |
Peribronchial consolidations, n (%) | 46 (56.8) | 21 (52.5) | 25 (61.0) | 0.441 |
Diffuse ground-glass opacities, n (%) | 17 (21.0) | 9 (22.5) | 8 (19.5) | 0.741 |
Lesions typical of invasive aspergillosis on CT scan, n (%) | 30 (37.0) | 15 (37.5) | 15 (36.6) | 0.932 |